Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

Imipramine Hydrochloride and Lomustine for the Treatment of Recurrent Glioblastoma

Trial Status: closed to accrual and intervention

This phase II trial studies the effects of imipramine hydrochloride and lomustine in treating patients with glioblastoma that has come back (recurrent). Imipramine hydrochloride is used to relieve symptoms of depression. Imipramine hydrochloride may penetrate the blood-brain-barrier (a tissue barrier which does not allow most cancer drugs to penetrate from circulating blood into the brain) and reach the cancer. Chemotherapy drugs, such as lomustine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving imipramine hydrochloride in combination with lomustine may help treat patients with glioblastoma.